Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XM007
- Development stage
- Preclinical
- Lead developer
- Hefei Xingmou Biotechnology
- Modality
- Gene Therapies
01
Overview
XM007 is an investigational drug candidate being developed by Hefei Xingmou Biotechnology (also known as StarryGene) for the treatment of obesity. As of 2024, the program is in the preclinical research and activity validation stage. Hefei Xingmou Biotechnology is a China-based biotechnology company that primarily focuses on gene therapy platforms, particularly for ophthalmic diseases; however, XM007 represents an expansion of their pipeline into metabolic indications. Specific details regarding the molecular target, mechanism of action, and delivery modality of XM007 have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on XM007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XM007.